Add to a list

Inactive Instrument

Seagen Inc. Share Price

SGEN

US81181C1045

Biotechnology & Medical Research

Analysts' recommendations: Seagen Inc.

15/12/23	Analyst recommendations: Adobe, Blackrock, Roblox, Snap, US Bancorp...
24/03/23	Berenberg Bank Downgrades Seagen to Hold From Buy, Adjusts Price Target to $229 From $170	MT
21/03/23	TD Cowen Raises Price Target on Seagen to $229 From $145, Maintains Market Perform Rating	MT
20/03/23	Truist Securities Adjusts Price Target on Seagen to $229 From $152, Maintains Hold Rating	MT
15/03/23	Morgan Stanley Downgrades Seagen to Equalweight From Overweight, Adjusts Price Target to $229 From $173	MT

More recommendations

News in other languages: Seagen Inc.

05/02/24	Übernahmegerüchte schicken Morphosys auf Hoch seit Juli 2021
15/12/23	Pfizer, Inc: un ciclo per niente?
15/12/23	Pfizer : le dividende augmente, le titre rebondit
15/12/23	ÜBERBLICK/Anstehende Indexänderungen
14/12/23	Pfizer, Inc.: een cyclus voor niets?

More news

Managers and Directors: Seagen Inc.

Manager	Title	Age	Since
Chris Boshoff PSD	President	-	13/12/2023
Deborah Baron PRN	Corporate Officer/Principal	57	-
Alison Marquez O'Neill SEC	Corporate Secretary	-	-

Director	Title	Age	Since
Deborah Baron BRD	Director/Board Member	57	13/12/2023
Alison Marquez O'Neill BRD	Director/Board Member	-	13/12/2023

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEAGEN INC.	-0.07%	+4.77%	-	-	43.15B
WUXI APPTEC CO., LTD.	-3.10%	-4.19%	+32.67%	+59.47%	63.48B
ARGENX SE	+1.25%	+0.48%	+10.95%	+80.70%	54.55B
LONZA GROUP AG	-0.41%	+1.73%	+9.89%	+102.10%	53.59B
IQVIA HOLDINGS INC.	-0.75%	+1.38%	+24.89%	+50.91%	44.75B
BEONE MEDICINES AG	-1.30%	-4.80%	+16.05%	+114.76%	41.62B
REVOLUTION MEDICINES, INC.	+1.26%	-5.26%	+221.12%	+900.64%	39.91B
CELLTRION, INC.	-0.74%	-4.46%	+11.00%	+44.65%	32.47B
GENMAB A/S	+0.10%	+15.18%	+60.27%	+49.33%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.54%	-6.40%	+25.79%	-8.44%	23.36B
Average	+0.00%	-1.19%	+45.85%	+154.90%	42.27B
Weighted average by Cap.	-0.27%	-1.27%	+43.05%	+155.67%

See all sector performances

Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).

Employees

3,256

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
SGEN Stock

The best tools reserved for subscribers to boost the performance of your investments!

16/05/24	Fitch Affirms and Withdraws Pfizer's Ratings; Outlook Stable	AQ
28/03/24	Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential	AQ
29/02/24	Seagen Requests Director Review Of Unpatentability Decision In Adcetris® Patent PGR	AQ
30/01/24	PTAB Issues Final Written Decision Finding Seagen Antibody-Drug Conjugate Patent Claims To Be Unpatentable	AQ
10/01/24	Fitch Affirms Pfizer's Long-Term IDR at 'A'; Outlook Stable	AQ

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/12/23	Nancy Simonian	Issuer sale	Director	127,934	0.0678%
14/12/23	David Epstein	Issuer sale	Chief Executive Officer	643,595	0.3411%
14/12/23	John Orwin	Issuer sale	Director	97,934	0.0519%

Seagen Inc. Share Price

Stocks

SGEN

US81181C1045

Biotechnology & Medical Research

Latest news: Seagen Inc.

Analysts' recommendations: Seagen Inc.

Press Releases: Seagen Inc.

News in other languages: Seagen Inc.

Quotes and Performance

Managers and Directors: Seagen Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

05/02/24	Takeover rumors send Morphosys to high since July 2021	DP
18/12/23	Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Biotechnology Select Industry Index	CI
18/12/23	Seagen Inc.(NasdaqGS:SGEN) dropped from S&P TMI Index	CI
18/12/23	Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Global BMI Index	CI
15/12/23	Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev	DJ
15/12/23	Pfizer: dividend increases, stock rebounds
15/12/23	Euphoria subsides for Triple-Witching Day
15/12/23	Analyst recommendations: Adobe, Blackrock, Roblox, Snap, US Bancorp...
15/12/23	HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	MT
15/12/23	Seagen Inc.(NasdaqGM:SGEN) dropped from NASDAQ Biotechnology Index	CI
15/12/23	Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ-100 Index	CI
15/12/23	Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index	CI
14/12/23	Pfizer, Inc: A cycle for nothing?